Balázs Szécsi, Richárd Sinkó, Alexandra Vereb, Dmitry Khochanskiy, Kálmán Benke, Tamás Radovits, Bálint Lakatos, Andrea Kőszegi, Eszter Losoncz, Szilvia Kugler, Márk Szabó, Béla Merkely, Andrea Székely, Balázs Gereben
{"title":"The Perioperative Period of Heart Transplantation Is Affected by Thyroid Hormone Status.","authors":"Balázs Szécsi, Richárd Sinkó, Alexandra Vereb, Dmitry Khochanskiy, Kálmán Benke, Tamás Radovits, Bálint Lakatos, Andrea Kőszegi, Eszter Losoncz, Szilvia Kugler, Márk Szabó, Béla Merkely, Andrea Székely, Balázs Gereben","doi":"10.1089/thy.2023.0628","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Orthotopic heart transplantation (HTx) is a long-term surgical therapeutic approach for patients with end-stage heart failure. The objective of the present study was to uncover associations between altered thyroid hormone (TH) status and adverse outcomes after HTx. <b><i>Methods:</i></b> In this prospective, single-center cohort study, 283 patients underwent HTx between 2013 and 2020 at the Heart and Vascular Center of Semmelweis University in Hungary. We measured serum free triiodothyronine (fT3), free thyroxine (fT4), and thyrotropin (TSH) pre- and postoperatively. TaqMan qPCR was used to measure type 2 deiodinase and type 3 deiodinase mRNA (<i>Dio2</i> and <i>Dio3</i>, respectively) levels from the diseased heart bioptates. To assess the local TH action of the heart, mRNA levels of <i>Hcn2</i> and <i>Myh7</i> were measured in a subgroup of patients receiving extracorporeal membrane oxygenation (ECMO) postoperatively. Groups were compared using nonparametric tests. Cox regression analysis and logistic regression test were used to investigate the outcomes. The connection between serum TH parameters and cardiac gene expressions was assessed using linear regression. <b><i>Results:</i></b> Serum TSH (<i>p</i> = 0.009), fT3 (<i>p</i> < 0.001), and fT4 (<i>p</i> < 0.001) levels were lower after HTx than preoperatively. Levothyroxine (LT4) administered to donors was associated with better survival after 30 days (<i>p</i> = 0.049). LT4 replacement given to recipients after HTx was associated with better survival after 30 days (<i>p</i> = 0.018), 1 year (<i>p</i> = 0.002), and 2 years (<i>p</i> = 0.001). <i>Dio3</i> mRNA level was significantly increased in patients who were treated with ECMO (<i>p</i> = 0.026), left ventricular assist device (LVAD) (<i>p</i> = 0.008), and biventricular assist device (BiVAD) (<i>p</i> = 0.013) preoperatively, and ECMO (<i>p</i> = 0.042) postoperatively, compared with those who did not require any type of mechanical circulatory support (MCS). We found no significant difference in the expression of the <i>Hcn2</i> and <i>Myh7</i> marker genes between patients on postoperative ECMO and those without MCS, and neither did they correlate with serum hormone levels (<i>p</i> = 0.519 and <i>p</i> = 0.056, respectively). <b><i>Conclusions:</i></b> We conclude that TH status plays an important role in HTx patients, and monitoring of TH status in the perioperative period may contribute to improved treatment outcomes. Our findings require independent confirmation in a randomized controlled clinical trial.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"774-784"},"PeriodicalIF":5.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/thy.2023.0628","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Orthotopic heart transplantation (HTx) is a long-term surgical therapeutic approach for patients with end-stage heart failure. The objective of the present study was to uncover associations between altered thyroid hormone (TH) status and adverse outcomes after HTx. Methods: In this prospective, single-center cohort study, 283 patients underwent HTx between 2013 and 2020 at the Heart and Vascular Center of Semmelweis University in Hungary. We measured serum free triiodothyronine (fT3), free thyroxine (fT4), and thyrotropin (TSH) pre- and postoperatively. TaqMan qPCR was used to measure type 2 deiodinase and type 3 deiodinase mRNA (Dio2 and Dio3, respectively) levels from the diseased heart bioptates. To assess the local TH action of the heart, mRNA levels of Hcn2 and Myh7 were measured in a subgroup of patients receiving extracorporeal membrane oxygenation (ECMO) postoperatively. Groups were compared using nonparametric tests. Cox regression analysis and logistic regression test were used to investigate the outcomes. The connection between serum TH parameters and cardiac gene expressions was assessed using linear regression. Results: Serum TSH (p = 0.009), fT3 (p < 0.001), and fT4 (p < 0.001) levels were lower after HTx than preoperatively. Levothyroxine (LT4) administered to donors was associated with better survival after 30 days (p = 0.049). LT4 replacement given to recipients after HTx was associated with better survival after 30 days (p = 0.018), 1 year (p = 0.002), and 2 years (p = 0.001). Dio3 mRNA level was significantly increased in patients who were treated with ECMO (p = 0.026), left ventricular assist device (LVAD) (p = 0.008), and biventricular assist device (BiVAD) (p = 0.013) preoperatively, and ECMO (p = 0.042) postoperatively, compared with those who did not require any type of mechanical circulatory support (MCS). We found no significant difference in the expression of the Hcn2 and Myh7 marker genes between patients on postoperative ECMO and those without MCS, and neither did they correlate with serum hormone levels (p = 0.519 and p = 0.056, respectively). Conclusions: We conclude that TH status plays an important role in HTx patients, and monitoring of TH status in the perioperative period may contribute to improved treatment outcomes. Our findings require independent confirmation in a randomized controlled clinical trial.
期刊介绍:
This authoritative journal program, including the monthly flagship journal Thyroid, Clinical Thyroidology® (monthly), and VideoEndocrinology™ (quarterly), delivers in-depth coverage on topics from clinical application and primary care, to the latest advances in diagnostic imaging and surgical techniques and technologies, designed to optimize patient care and outcomes.
Thyroid is the leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. The Journal delivers the latest findings on topics from primary care to clinical application, and is the exclusive source for the authoritative and updated American Thyroid Association (ATA) Guidelines for Managing Thyroid Disease.